• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Patrick P. Gleason Addresses the Impact of Out-of-Pocket Costs on Adherence and Outcomes

Article

Patrick P. Gleason, PharmD, Director of Clinical Outcomes Assessment, Prime Therapeutics, discusses the rates at which patients will not follow a prescribed therapeutic plan due to cost-sharing. Specifically, patients starting multiple sclerosis, rheumatoid arthritis, and oral oncology medication regimens with more than a $100 cost-share will be less likely to start the drug therapy.

Patrick P. Gleason, PharmD, Director of Clinical Outcomes Assessment, Prime Therapeutics, discusses the rates at which patients will not follow a prescribed therapeutic plan due to cost-sharing. Specifically, patients starting multiple sclerosis, rheumatoid arthritis, and oral oncology medication regimens with more than a $100 cost-share will be less likely to start the drug therapy.

Related Videos
Dr Ola Landgren
David Awad, PharmD, BCOP
Gordon Crofoot, MD, PA
Jaime Almandoz, MD, MBA
Screenshot of Coral Omene, MD, PhD
Dr Brian Slomovitz
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy (AMCP)
ASCO 2025
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.